0.00Open0.00Pre Close0 Volume0 Open Interest17.00Strike Price0.00Turnover0.00%IV-82.21%PremiumJan 17, 2025Expiry Date7.67Intrinsic Value100Multiplier0DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma1.22Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Omeros Stock Discussion
how long will the hold off volume before reaching above 30
Omeros’ Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA
Omeros (OMER) announced successful results from its narsoplimab pivotal trial for treating transplant-associated thrombotic microangiopathy (TA-TMA). The primary statistical analysis showed that patients treated with narsoplimab had an over 3-fold reduction in mortality risk (hazard ratio = 0.32) compared to untreated p...
No comment yet